Substance Name: Figitumumab [USAN:INN]
RN: 943453-46-1
UNII: VE267FC2UB
Notes
- An anti-insulin-like growth factor-I receptor monoclonal antibody in Phase I clinical trials.
- An anti-insulin-like growth factor-I receptor monoclonal antibody in Phase I clinical trials.
NCI: A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. IGF1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival. (NCI Thesaurus)
Molecular Formula
- Unspecified
Classification Code
- Treatment of Cancer
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Names and Synonyms
Name of Substance
- Figitumumab [USAN:INN]
Synonyms
- CP 751,871
- CP 751871
- CP-751,871
- CP-751871
- CP751,871
- CP751871
- Figitumumab
- UNII-VE267FC2UB
Systematic Name
- Immunoglobulin G2, anti-(human insulin-like growth factor I receptor)(human monoclonal CP-751,871 clone 2.13.2 heavy chain) disulfide with human monoclonal CP-751,871 clone 2.13.2 light chain, dimer
Registry Numbers
CAS Registry Number
- 943453-46-1
FDA UNII
- VE267FC2UB
System Generated Number
- 0943453461